Marks & Clerk‘s offering has noteworthy abilities handling complex patent matters for clients spanning sectors including electronics and software, medtech, pharma and life sciences, amongst many others. Its workload incorporates advising on multi-jurisdictional patent portfolio management, freedom to operate, patent filings and related strategy. Additionally, the team is experienced acting in litigious contexts before the UPC and various UK courts, as well as in EPO opposition matters. Names to note include Will Nieuwenhuys who manages global portfolios, prosecutes patents in UK courts and before the EPO and handles patent drafting matters, and Thomas Prock who leads the team’s UPC group and harnesses expertise across various contentious matters. The practice is overseen by Simon Mounteney and Robin Oxley. Sheila Wallace retired in April 2024.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
- 'They know their stuff and are trustworthy.'
- 'Every member of the Marks & Clerk patent team is both personable and has exceptional intellect to quickly understand all types of technology and apply the necessary expertise to advocate for a successful outcome.'
Key clients
- AbbVie
- AB-InBev
Work highlights
Advising Daiichi Sankyo on patent and SPC portfolios relating to antibody-drug conjugates (ADCs) for treatment of cancers, including important commercial products.
Practice head
Simon Mounteney; Robin Oxley
Other key lawyers
Will Nieuwenhuys; Thomas Prock; Jonathan Stafford; Daniel Sizer; Matthew Jefferies; David Lang; Sophie Topham; Pam Bryer; Peter Roberts